Neuland Laboratories reported a decline in Q2 FY27 revenue to Rs 457.2 crore and PAT to Rs 51.1 crore, citing the 'lumpy' nature of its CDMO business. Despite the quarterly dip, management maintained its growth outlook for FY27 and FY28. The company is aggressively scaling its peptide API capacity and investing in a new R&D center, with capital expenditure plans totaling Rs 1,700-1,800 crore over the next three years to drive long-term expansion.
Neuland Laboratories Q2 Profit Declines to Rs 51.1 Crore
Revenue for the quarter stands at Rs 457.2 crore compared to Rs 516.1 crore in Q2 FY26.
Reader Takeaway: Management maintains growth guidance for FY27/28 despite quarterly CDMO volatility and high customer concentration risks.
What just happened
Neuland Laboratories has released its Q2 FY27 earnings, reporting a total income of Rs 457.2 crore, down from Rs 516.1 crore in the year-ago period. Profit After Tax (PAT) stood at Rs 51.1 crore, compared to Rs 96.5 crore in Q2 FY26. EBITDA margins softened to 22.9% from 30.4% in the same quarter last year. The company noted that these figures are influenced by the inherent lumpiness of the Contract Development and Manufacturing Organization (CDMO) business model.
Why this matters
The results reflect the volatility often associated with high-value pharmaceutical manufacturing where revenue recognition depends on specific project milestones and shipment timelines. While the quarterly performance appears muted, management has explicitly reiterated that their growth expectations for the full fiscal years 2027 and 2028 remain unchanged.
The backstory
Neuland is currently in a major growth phase, having commissioned a new peptide block at its Unit One facility. This infrastructure is a strategic bet on the company's future as a dominant player in the peptide API market. Additionally, the company has secured 134 acres of land in Kakinada, Andhra Pradesh, intended to serve as a long-term foundation for industrial scaling.
Risks to watch
The company faces notable concentration risk, with its top five customers accounting for 68% of total revenue. Furthermore, the business is highly dependent on individual large-molecule projects, which inherently creates uneven quarterly revenue cycles. Success in the newly commissioned peptide segment depends heavily on upcoming validation processes and the eventual signing of commercial supply agreements.
What to track next
Investors should monitor the timeline for peptide revenue, as management expects Process Performance Qualification (PPQ) revenues to begin within 6-9 months, with commercial-scale revenue likely appearing in the next 1.5 to 2 years. The company's planned capital expenditure of Rs 1,700–1,800 crore over the next three years will also be a critical metric to track regarding cash flow management and project execution.